MedPath

TO KNOW ABOUT HOW THE IMMUNOHISTOCHEMICAL MARKERS PD-1 AND PD-L1 WILL EXPRESS IN BREAST CARCINOMA AND TO CORRELATE WITH IMMUNOTHERAPEUTIC INTERVENTIO

Not Applicable
Conditions
Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
Registration Number
CTRI/2023/07/055103
Lead Sponsor
Jawaharlal Nehru Medical College
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

All cases having a histopathological diagnosis of breast carcinoma and all modified radical mastectomy specimens.

Exclusion Criteria

Cases of adenomas, malignant lymphomas, myoepithelial lesions, nipple tumors, fibroepithelial tumors, and mesenchymal tumors, in male patients having breast carcinoma.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath